DNA Sequencing Markets: Global Analysis and Opportunity Evaluation 2016 - 2020
This market report gives a comprehensive and easy-to-review analysis of the DNA sequencing market 2016 – 2020. It provides key market data and identifies new and emerging opportunities across this growing field. The analysis is based on primary data disclosed by experienced end-users’ on their current sequencing practices and their plans over the next three. Its findings provide a wealth of market information on the sequencing market and enables suppliers to reduce costs, identify new markets and compete more effectively in the global marketplace.
The last decade has seen remarkable innovation and development in the nucleotide sequencing field. Today, a number of powerful high–throughput sequencing technologies are available and are being used to address an increasingly diverse range of biological problems. The quantitative scale and efficiencies of next-generation sequencing platforms are also seeing unprecedented progress and growth in many areas of fundamental research. Also, dramatic reductions in the associated costs and the operational complexities of these techniques are opening up applications in areas that would have been unimaginable just a decade ago.
This report presents the findings of a new global study of nucleotide sequencing, which profiled the use of these techniques from the end-user’s perspective. This study, which evaluated end-users' current sequencing practices and three-year plans, investigated market growth, the competitive positions of global sequencing suppliers, sequencing laboratory location, preferred external Laboratories, sequencing methods, sequencing laboratory instruments, company suppliers, applications, clonal amplification, diseases, nucleotide types, software, sequencing performance, numbers of samples, disease Biomarkers, study samples, sample preparation, advantages and disadvantages, fields, participant roles, organisation type, experience, countries and regions.
Biopharm Reports' specialised market studies are designed to assist suppliers and developers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies assist suppliers to sell into these markets, and also support innovation and strategic planning. The following study areas were investigated:
Companies mentioned
More than 60 companies are mentioned in this report, namely 5-Prime, Affymetrix, Agencourt (Beckman Coulter), Agilent, AGRF, Ambion (Lifetech), AppliChem, Applied Biosystems, BD, Beckman, BGI, Bioline, Biomerieux, Biometra, Bio-Rad, Celera, Complete Genomics, DNA Technologies, Eppendorf, Eurofins, Exiqon, Fermentas, Fisher Scientific, Fluidigm, GE, Illumina, In-House, Integrated DNA Technologies (IDT), Invitrogen (Lifetech), Ion Torrent (LifeTech), Kapa Biosystems, Labgene, LGC Genomics, Li-Cor, Life technologies, Lucigen, Macherey-Nagel, Macrogen, Mallinckrodt Baker, Millennium Bioscience, MO BIO, Molecular Research Center, MP Biomedical, MWG Operon, New England Biolabs, Nugen, Orion Genomics, Oxford Nanopore, Pacific Biosciences, Perkin Elmer, Promega, Qiagen, Roche (454), Roche Diagnostics, Sangon Biotech, Seegene, Sequenom, Sigma-Aldrich, Solis BioDyne, Takara/Clontech, Tecan, Thermo Scientific, USB Corp and Zymo Research.
Sequencing Location: The locations of the laboratory where Sequencer's sequencing work are carried out, where the options considered were their own laboratory, and external laboratory or both own laboratory and external laboratory.
Preferred External Laboratories: Those sequencers who indicated that they contracted-out their sequencing activities to external laboratories were asked to indicate their preferred laboratories for this activity.
Growth: Based on recent trends in the numbers of sequencing studies carried out in their laboratories, end-users' estimates of by how much (% increase or % decrease) their laboratory use of sequencing has changed over the last three years. Also, based on current trends in the numbers of sequencing studies carried out in their laboratories, end-users' estimates of by how much (% increase or % decrease) they anticipate their laboratory use of sequencing will change over the next three years.
Sequencing methods: Sequencer’s main use of specific sequencing techniques, both currently and anticipated in three years from now, where the techniques considered (23 different methods) were 454 Pyrosequencing (Roche), Chain Termination Method (Sanger Sequencing), DArT Seq (Diversity Array Technology), DNA Nanoball Sequencing (Complete Genomics), DNA Nanopore Sequencing (Oxford Nanopore Technologies), Electron Microscopy-Based Sequencing (ZS Genetics), Gene Electronic Nano-Integrated Ultra-Sensitive Technology (Geneapsys), Ion Torrent (Thermo Fisher), Massively Parallel Signature Sequencing (Illumina), Microfluidic Sequencing (GnuBIO), Nanowire Biosensor Sequencing Technology (Quantumdx), RAD Sequencing (University Oregon/Floragenex), Sequencing by Hybridization (Affymetrix), Sequencing by Hybridization-Assisted Pore-Based sequencing (NABsys), Sequencing by mass spectrometry, Sequencing by Reversible-Hybridization (Complete Genomics), Sequencing by Synthesis (Illumina/Solexa), Shotgun Sequencing/Chain Termination (Sanger), Single Molecule Nanopore Sequencing (Noblegen Biosciences), Single Molecule Real-Time Sequencing (Pacific Biosciences), Single-molecule Semiconductor-Based Sequencing (Genia/Roche), SOLiD Sequencing (Applied Biosystems), Tunnelling Current DNA sequencing and any others.
Sequencing Instruments: Sequencer’s use of specific sequencing instruments, both currently and anticipated in three years from now, where the instruments considered (26 different systems) were Applied Biosystems: 3500 Genetic Analyzer, Applied Biosystems: 3500xL Genetic Analyzer, Applied Biosystems: 3730 DNA Analyzer, Applied Biosystems: 3730xl DNA Analyzer, Applied Biosystems: SOLiD Next-Generation System, BGI: BGISEQ-500 NGS System, Diversity Array Technology: Scanner (DArT Seq), Geneapsys: GENIUS, GnuBio: GnuBIO instrument, Illumina: HiSeq 2500, Illumina: HiSeq 3000/HiSeq 4000, Illumina: HiSeq X Five, Illumina: HiSeq X Ten, Illumina: MiniSeq, Illumina: MiSeq, Illumina: MiSeq FGx, Illumina: MiSeqDx, Illumina: NextSeq 500, Oxford Nanopore: GridION System, Oxford Nanopore: MinION, Oxford Nanopore: PromethION, Pacific Biosciences: PacBio RS II, Pacific Biosciences: Sequel System, Thermo Fisher: 3500 Genetic Analyser (Sanger), Thermo Fisher: Ion PGM System Ion PGM System, Thermo Fisher: Ion Proton System for NGS and any others.
External Laboratory Sequencing Service Providers: As part of this market study, external laboratories that provide nucleotide sequencing services to the end-users profiled, were also invesigated and are identified in this report.
Company Suppliers: End-users' current main suppliers of sequencing instruments, products or consumables, as well as those companies they anticipate will be supplying these products to their laboratories in three years from now, where 93 companies are considered, namely, 5-Prime, Abbott, Affymetrix, Agencourt (Beckman Coulter), Agilent, AGRF, Ambion (Lifetech), Anatech, Answer Choices, AppliChem, Applied Biosystems, BD, Beckman, BGI, Bioline, Biomerieux, Biometra, BioNanomatrix, Bioneer, Bionobile, Bionobile, Bio-Rad, Celera, Chemagen (PE), Complete Genomics, DNA Technologies, Eppendorf, Eurofins, EURx, Exiqon, Fermentas, Fisher Scientific, Fluidigm, FugiFilm, GE, GenDx, Halcyon Molecular, Illumina, In-House, Inqaba Biotechnology, Integrated DNA Technologies (IDT), Intelligent BioSystems, Invitek, Invitrogen (Lifetech), Ion Torrent (LifeTech), Kapa Biosystems, Labgene, LGC Genomics, Li-Cor, Life technologies, Lucigen, Macherey-Nagel, Macrogen, Mallinckrodt Baker, Millennium Bioscience, MO BIO, Molecular Research Center, MP Biomedical, MWG Operon, NABsys, New England Biolabs, Nexttec, Nippon Gene, Nugen, Orion Genomics, Oxford Nanopore, Pacific Biosciences, Panomics,
Perkin Elmer, Phoenix (Microarray), Primm Biotech, Promega, Qiagen, r-Biopharm, Roche, Roche (454), Roche Diagnostics, Roth, Sangon Biotech, Seegene, SeqLL, Sequenom, Sequiserve, Siemens, Sigma-Aldrich, Solis BioDyne, Stab Vida, Takara/Clontech, Tecan, Thermo Scientific, USB Corp, Vivantis, Zymo Research and any others.
Applications: End-users' current main applications of sequencing as well as the applications they anticipate using in three years from now, where the applications considered were Allele size detection, Aneuploidy and CNV analysis, Antibacterial resistance analysis, Antiviral resistance analysis, Bacterial typing, ChIP-Seq, Cloning, Complex populations, De Novo Sequencing, Detection, identification of bacteria, Detection, identification of viruses, Diverse gene polymorphisms, DNA barcoding, species identifications, DNA quantification, Epigenome characterization, Exome sequencing, Fragment analysis for epidemiological analysis, Full 16S sequencing for identification and phylogeny, Gene expression (mRNA), Gene mutations or alterations, Gene variants in disease, Genetic mapping, Genome Resequencing, Genotyping by Sequencing, Genotyping of microorganisms, Haplotypes, Immune diversity, Metagenomics, Methylation Sequencing, Microbial Sequencing, MicroRNA Studies, Microsatellites, Phylodynamic analyses, Rapid Diagnostic - Genetic Markers, Regulatory elements, Ribosomal DNA (rRNA) Studies, RNA Sequencing, Short Tandem Repeat Analysis, Single Nucleotide Polymorphisms, Single-Strand Conformation Polymorphism, Small insertions or deletions, Small Interfering RNA (siRNA) Studies, Small Nuclear RNA (snRNA) Studies, Small RNA and miRNA Sequencing, Targeted DNA sequencing, Targeted Resequencing, Tissue typing, Total RNA Sequencing (Transcriptome), Transfer RNA (tRNA) Studies, Ultra-Low-Input/Single-Cell RNA-Seq, Viral Typing, Whole-Genome Sequencing and any others.
Clonal Amplification: End-users' clonal amplifications methods used in their nucleotide sequencing, both currently and anticipated in three years, where the methods considered were Bridge PCR Amplification, Emulsion PCR Amplification, Rolling Circle Amplification and None (e.g. Single Molecule Sequencing).
Diseases: End-user's current sequencing activities, and those sequencing activities they anticipate in three years from now, relating to specific disease areas, namely Antimicrobial resistance, Arthritis, Asthma and allergy, Autoimmune Diseases, Bone Metabolism, Cancer, Cardiovascular, Central Nervous System, Dentistry, Dermatology, Endocrine, Gastrointestinal, Genetic diseases, Genito-Urinary System, Haematology, Hearing Loss, Immunodeficiency, Infections, Infertility, Inflammation, Liver disease, Metabolic Disorders, Musculoskeletal Disorders, None, Nutrition, Obstetrics and Gynaecology, Ophthalmology, Pain, Phytopathology, Psychiatry, Rare diseases, Reproduction, Respiratory, Sexually transmitted infections, Skin, Stem cells, Transplantation medicine, Vector borne disease, Virus diseases and any others.
Nucleotide Types: Main nucleic acid types currently sequenced, as well as those anticipated to be sequenced in three years from now, where the nucleic acids considered were Archaeal DNA, Bacterial DNA, Bacterial PCR amplicons, Bisulfite-converted DNA, cDNA, cell free miRNA, fungal DNA, Genomic DNA, ITS region, Metagenomic DNA, MicroRNA, Mitochondrial DNA, mRNA, Noncoding RNA, Nuclear DNA genes, Pathogen RNA/DNA, piRNA, Plant viral RNA or DNA, Plasma Cell Free DNA, Plasmid DNA, Prokaryotic small RNA, Protist DNA, Ribosomal RNA (rRNA), Small interfering RNA (siRNA), Small nuclear RNA (snRNA), Total RNA, Transfer RNA (tRNA), Tumour Cell DNA, Viral DNA, Viral PCR amplicons, Viral RNA and any others.
Software: Sequencers main software programs used for their nucleotide sequencing activities and those considered (n = 387) were ABA (Raphaelet al.), ABySS (Simpson et al.), ACANA (Huang et al.), ACT (Sanger), Alamut (Interactive Biosoftware), ALE (Blandy et al.), AlignMe (Stamm et al.), ALLPATHS (Broad Institute), Alta-cyclic (Omictools), AMAP (Schwartz et al.), AnnHyb (MyBiosoftware), Annovar (Open Bioinformatics), anon. (Powell et al.), Answer Choices, Artemis (Sanger), Augustus (Gottingen), AVID (Vista), BAliBASE (Thompson et al.), BAli-Phy (Redelings et al.), BarraCUDA (GPL), Base-By-Base (Brodie et al.), BBMap (Source Forge), Beast (Drummond et al.), Belvu (Sanger), BFAST (GPL), BigBWA (Omictools), Bioconductor (Aboyoun et al.), BioEdit (Ibis), BioLinux (EON), Biomart (Ensembl), BioNumerics (Applied Maths), BioPerl dpAlign (Chan et al.), Biopieces (Biostars), BisMark (Babraham), BLAST (Altschul et al.), BLASTN (NCBI), BLASTZ,LASTZ (Schwartz et al.), BLAT (Non-Commercial Academic), BLOCKS (Molbio-Tools), Bowtie (Artistic License), BS-Seq (UCLA), Bustard (Illumina), BWA (GPL), BWA-PSSM (Bio-BWA), Cap3 (Genome), Casava (Illumina), CASHX (Non-Commercial Academic), CEQ (Beckman et al.), CHAOS/DIALIGN (Brudno et al.), ChIP-Seq (DNASTar), Chromas (Technelysium), Clarity (Genologics), CLC Genomic Workbench (CLCBio), Clone Manager (CLCBio), Cloudburst (Artistic License), ClustalW (Thompson et al.), CNVnator (Omictools), CNV-Seq (Chao et al.), CodonCode Aligner (Richterich et al.), Compass (Sadreyev, et al.), Contig Express (Contig), CS-BLAST (Angermueller et al.), CUDA-EC (Omictools), CUDAlign (Source Forge), CUDA-MEME (MyBiosoftware), CUDASW++ (Liu et al.), Cufflinks (Cole-trapnell), CUSHAW (GPL), CUSHAW2 (GPL), CUSHAW2-GPU (GPL), CUSHAW3 (Source Forge), Custom Designed (In-House), Dalliance (Omictools), dbSNP (Open Source), DECIPHER (DecipherProject), DESeq (Bioconductor), DIALIGN-TX and DIALIGN-T (Subramanian et al.), DIAMOND (GitHub), DNA Alignment (Roehl et al.), DNA Baser Sequence Assembler (Heracle BioSoft), DNADot (Bowen et al.), DNAsp (UBEdu), DNASTAR (DNAStar), DOTLET (Pagni et al.), dpAlign (BioPerl), drFAST (BSD), EagleView (Boston College), Edena (Hernandez ), EDNA (Salama et al.), ELAND (Illumina), EMBL-EBI (EBI Ac), eMOTIF (Stanford), Ensemble (Ensembl), ERANGE (Wold Lab), ERNE (GPL), EULER-SR (Chaisson ), Excel (Open Source), Exonerate (Guy St C Slater et al.), ExpressionSuite (Thermo Fisher), FASTA (Faster Biotech), Fastpcr (PrimerDigital), FastQC (Babraham), fastseq (Helical), fastx-tools (Hannon), FEAST (Hudek et al.), FindPeaks (Bainbridge et al.), FMM (Open Source), FreeBayes (Omictools), FSA (Bradley et al.), Galaxy (Galaxy), GapMis (Frousios et al.), GASSST (Omictools), GATK (Broad Institute), GEM (Non-Commercial Academic), GenAlex (BiologyAssets), Genalice MAP (Genalice), GenDB (Open Source), Gene Construction Kit (Textco), Gene Mapper (ABI), Gene tex (Genetex), GeneInsight (Geneinsight), Geneious (Drummond et al.), Geneious Assembler (Geneious), GeneMapper® Software (ABI), Genologics (Illumina), Genomatix (Genomatix), Genome Browser (UCSC), Genome Compiler (Genome Compiler), GenomeMapper (1001 Genomes project), GenomeStudio Software (Illumina), Genomics Workbench (CLCBio), Genoogle (Genoogle), Genotyper (ABI), GenSearch (Phenosystems), GensearchNGS (Omictools), Geospiza (Geospiza et al.), GGSEARCH, GLSEARCH (Pearson et al.), Gibbs motif sampler (Omictools), Glimmer (CBCD), GLProbs (Omictools), GMAP and GSNAP (Non-Commercial Academic), G-Mo.R-Se (CNS, France), GNUMAP (Omictools), G-PAS (Frohmberg et al.), GS Amplicon Variant Analyzer (Roche), HapCompass (Omictools), HGMD (Biobase), HHpred / HHsearch (Soding et al.), HiSeq Software (Illumina), HIVE-hexagon (Hive), HMMER (Durbin et al.), HMMTOP (SACS), HOMSTRAD (Mizuguchi et al.), Htseq (Huber et al.), HyPhy (Hyphy et al.), Ibis (Ibis), IDF (CSUni), IGV (Broad Institute), IMEX (Omictools), IMGT (IMGT), Infernal (Eddy), Ingenuity (Ingenuity), In-House (In-House), Ion Reporter (Thermo Fisher), Ion torrent (Thermo Fisher), iSAAC (Non-Commercial Academic), I-sites (Open Source), JAligner (Moustafa et al.), Jalview (Jalview), JCoils (CHEmbnet), KSync (Chivian et al.), Kalign (Lassmann et al.), KLAST (CLCBio), Kodon (Applied Maths), LALIGN (Pearson et al.), Lasergene (DNAStar), LAST (GPL), LASTZ (NCBI), LookSeq (Sanger), MACS (Zhang et al. ), MacVector (MacVector), MAFFT (Katoh et al.), Mage Platform (Genoscope), mAlign (Powell et al. ), Manattee (Manattee), MapNext (Sun-Yat Sen Univ), MapView (Sun-Yat Sen Univ), MAQ (GPL), MARNA (Siebert et al.), Matcher (Longden et al.), Mauve (Darlinglab), MAVID (Bray et al.), MCALIGN2 (Wang et al.), MEGA (Megasoft), MEME/MAST (Meme), MERCI (Bioinfo), Metacore (Omictools), MG RAST (Metagenomics), MGA (Omictools), Mira (Omictools), MIRA2 - MIRA (Source Forge), MirCheck (Mybiosoftware), Mirdeep2 (MDC Berlin), miREvo (Omictools), MiSeq (Illumina), MiSeq Software (Illumina), MOM (CS.CMU), MOSAIK (Stromberg et al. ), Mothur (Mothur), MPscan (Omictools), MrBayes (MrBayes), mrFAST and mrsFAST (BSD), MSA (Lipman et al.), MSAProbs (Liu et al.), MSeqDR (Open Source), Mulan (Mulan), MULTALIN (Corpet et al.), Multi-LAGAN (Brudno et al.), Multiz (Mybiosoftware), MUMmer (Kurtz et al.), MUSCLE (Edgar et al.), Mutation Surveyor (Softgenetics), mVista (Genome), MyRAST (Mybiosoftware), NCBI (Open Source), Needle (Bleasby et al.), NETGLYC (CBS), NetPrimer (PremierBiosoft), Newbler (Roche), NextGENe (Softgenetics), NextGenMap (Omictools), Ngila (Cartwright et al.), NISC (NIH), Novoalign & NovoalignCS (Non-Commercial Academic), NW-align (Zhang et al.), Omixon (Omixon), Opal (Wheeler et al.), Oxbench (Raghava et al.), PAL_finder (Source Forge), PALMapper (GPL), Pandaseq (Github), Panther (Omictools), Parasail (BMC), Partek (Partek), Pasa (Pasa), PASS (CRIBI), Path (Girdea et al.), PathSeq (Broad Institute), PatternHunter (Ma et al.), PAUP (Evolution), PeakSeq (Rozowsk et al.), Pecan (Paten et al.), PerM (GPL), PFAM (Sanger), PHI-Blast (NCBI), Phylo (McGill Bioinformatics), Phylogeny (Evolution), Phyloscan (NCBI), phyML (ATGC), Picard (Broad Institute), PicXAA (Omictools), PLAST-ncRNA (NCBI), PMS (Open Source), POA (Lee et al.), PolyBayesShort (Boston College), Polyphen (Harvard), Praline (Heringa et al.), PRATT (EBI Ac), PREFAB (Edgar et al.), Primer 3 (PremierBiosoft), PRIMEX (Open Source), Prism (ABI), ProbA (also propA) (Muckstein et al), Probalign (Roshan et al.), ProbCons (Do et al.), Prodigal (Omictools), PROMALS3D (Pei et al.), Proseq (Biosoft), PRRN/PRRP (Totoki et al), PSAlign (Sze et al.), PSI-BLAST (Altschul et al. ), PSI-Search (Li et al.), PyMOL (DeLano et al.), PyroBayes (Boston College), Python (DigitalBiol), QIIME (QIIME), Qpalma (De Bona et al. ), QuEST (Stanford), R (Open Source), RAST (Molbiotools), Ray (Denovo), RazerS (LGPL), RDP (NCBI), REAL, cREAL (GPL), REPuter (Kurtz et al.), Responses, Responses, RevTrans (Wernersson et al.), RMAP (GPL), rNA (GPL), RNASAT (Stanford), Rolexa (Bioconductor), RTG Investigator (Non-Commercial Academic), SABERTOOTH (Teichert et al.), SABmark (Van Walle et al.), SAGA (Notredame et al.), SAM (Krogh et al.), Satsuma (Grabherr et al.), ScalaBLAST (Oehmen et al.), ScanProsite (Prosite), Se-Al (Rambaut et al.), Seaview (Mybiosoftware), Segemehl (Non-Commercial Academic), SEQALN (Waterman et al.), SEQAN (Rausch et al.), SeqMan (DNAStar), SeqMap (Jiang et al.), SeqScape (Thermo Fisher), Sequence Scanner Software (ABI), Sequences Studio (Meskauskas et al.), Sequencher (Gene Codes Corp), Sequencing Analysis Software (ABI), Sequencing Analysis Viewer (Illumina), Sequerome (Bioinformatics.org), Sequilab (Lifescisoft), Serial Cloner (SerialBasics), SHARCGS (Dohm et al.), SHORE (1001 Genomes project), Shrec (Omictools), SHRiMP (Brudno et al.), Shuffle-LAGAN (Stanford), SIBsim4 / Sim4 (NEBC), SIM, GAP, NAP, LAP (Huang et al.), SISSRs (Jothi et al.), Slider (BCGSC), SlimSearch (EdwardsLab), SMART (Letunic et al.), SOAP, SOAP2, SOAP3 and SOAP3-dp (GPL), SOCS (Ondov et al.), SOLiD™ Software (ABI), SPA (Shen et al), SPAdes (Open Source), Splign (Open Source), SSAHA and SSAHA2 (Non-Commercial Academic), SSAKE (Omictools), SSEARCH (Pearson et al.), Staden (Source Forge), Stampy (Non-Commercial Academic), StatAlign (Novak et al.), Stemloc (Holmes et al.), SToRM (Omictools), stretcher (Longden et al.), Subread and Subjunc (GPL), SureCall (Agilent), SWAPHI (Open Source), SWAPHI-LS (Open Source), SWIFT suit (Rasmussen et al.), SWIPE (GNU), SXOligoSearch (Synamatix), Syngene (GeneTools), Tablet (Omictools), Taipan (Non-Commercial Academic), T-Coffee (Notredame et al.), TEIRESIAS (IBM), TopHat (Univ's Maryland/California ), Torrent (Thermo Fisher), tranalign (Williams et al.), Trinity (Strozzi et al.), UCHIME (Mothur), UCLUST (NEBC), UGENE (GPL), USEARCH (Drive5), VarScan (Source Forge), VCAKE (Omictools), Vector NTI (Thermo Fisher), VectorFriends (BioFriends team), VelociMapper (Omictools), Velvet (Zerbino et al), Vmatch (VMatch ), water (Bleasby et al.), wordmatch (Longden et al.), XMatchView (Warren et al. ), XpressAlign (Non-Commercial Academic), YASS (Noe et al), Zenbu (Omictools), ZOOM (Omictools) and any Others.
Sequencing Performance: Five areas of the performance of end-users' sequencing activities were investigated namely read length (bp) that they typically achieve in your sequencing work, the accuracy (%, single read, not consensus) that they believe they achieve in their work, the reads per run (in millions of bases) that they typically achieve in their work, the typical time per run (minutes, hours, days, weeks or months) in their sequencing work and the sequencing costs in terms of US$ per 1 million bases.
Numbers of samples: Sequencers estimates of the number of study samples they sequence in their laboratory, where the options were <1; 1; 1 to 2; 2 to 3; 3 to 4; 4 to 5; 5 to 7; 7 to 10; 10 to 15; 15 to 25; 25 to 40; 40 to 60; 60 to 100; 100 to 150; 150 to 200; 200 to 250 or 250.
Disease Biomarkers: Sequencers were asked if they use sequencing to research, discover or measure disease biomarkers, where the options were yes or no. Those who answered yes to this question were asked to indicate indicate which disease biomarkers they study in their sequencing work. These included Absolute DNA quantification, Alternative spliced variants, Bacteria detection, DNA methylation, Gene copy number, Gene expression, Gene mutations/polymorphisms, Haplotypes, microRNA, Protein mRNA quantification, Single nucleotide polymorphisms (SNPs), Small interfering RNA, Small nuclear RNA, SSRs or TRs, Tissue typing, Virus detection or any others.
Study samples: Sequencers were asked to indicate the main study samples in their sequencing activities where the options were Algal, Animal tissues, Archaeal cultures, Bacterial cultures, Bone, Cell isolates, Cells, Cerebrospinal fluid, Cultures, Dried blood, Embryos, Environmental samples, Faeces/Stools, Fermented foods, Foodstuffs, Fungal material, Genetic material, Human tissues, Insect material, In-vitro solutions, Isolated viruses, Marine, Marine invertebrates, Paraffin embedded tissue, Phage material, Plant material, Plasma, Protozoa, Respiratory fluids, Saliva, Semen, Serum, Soil, Swabs, Teeth, Urine, Venom, Water, Whole blood or any others.
Sample Preparation: Sequencers were asked to indicate the main sample preparation method(s) that they use in their sequencing activities, where the methods considered were solution-Phase Methods; Automated Solution-Phase Methods; Solid-Phase Methods; Automated Solid-Phase Methods or others. Sequencers were also asked to indicate if they used kit-based sample preparation products in your nucleotide sequencing activities. Those who did were invited to indicate their preferred suppliers.
Advantages and disadvantages: Sequencers were asked to indicate that they considered to be the main advantages and disadvantages of their most commonly used nucleotide sequencing techniques.
Fields: End-users' field or sector relating to their use of sequencing, including Bacteriology, Bioinformatics, Blood groups, Blood products, Cell research, Clinical research, Clinical trials, Conservation Genetics, Diagnostic screening, Diagnostics, Diagnostics research, Disease biomarkers, Disease research, Drug R&D, Drug targets, Environmental microbiology, Environmental tests, Evolutionary biology, Food monitoring, Forensics Genetics, Fundamental research, Genomics, Histology, HLA-Typing for transplantation, Immunology, Laboratory surveillance, Metagenomics, Microbiology, Mitochondrial DNA, Molecular Ecology, Molecular epidemiology, Molecular Systematics, Natural products, Parasitology, Paternity Testing, Phylogenetics, Plant Breeding, Plant Evolution, Plant Sciences, Population genetics, Preclinical research, Proteomics, Responses, Soil ecology, Taxonomy, Treatment monitoring, Virology and other.
Role: End-user's main role relating to their use of nucleotide sequencing, where the options were Laboratory Scientist, Physician or Clinician, Laboratory or Clinical Manager, Veterinarian and Other.
Organisation Type: End-users organisation type, where the options were Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation or other.
Experience: End-users' years of experience using nucleotide sequencing.
Job Title: End-user's job title.
Countries and Regions: End-users' countries and global regions; Asia, North America, South America, Africa (Sub-Saharan), Central America/Caribbean, Australia, New Zealand and Oceania and Middle East/North Africa/and Greater Arabia.
Participants: Names, organisation name and business email address.
- Current and 3-year market estimates provided by experienced end-users
- Recent Growth in sequencing and estimated growth over the next 3 years (±% change)
- Sequencing laboratory locations and preferred external laboratories
- Sequencing techniques used currently and anticipated in 3 years (±% change)
- Sequencing instruments used currently and anticipated in 3 years (±% change)
- Current sequencing suppliers and anticipated suppliers in 3 years (±% change)
- Current sequencing applications and anticipated applications in 3 years (±% change)
- Clonal amplification methods
- Read lengths, accuracy, reads per run, time per run and sequencing costs.
- Disease areas relating to sequencing now and in 3 years (±% change)
- Nucleotide types currently sequenced and anticipated in 3 years (±% change)
- Software used by sequencers
- Costs of sequencing per sample and associated nucleotide lengths
- Numbers of samples sequenced per month
- Disease biomarkers investigated using sequencing
- Biomarker disease areas and molecular types
- Sample preparation methods used in sequencing
- Purpose, fields or sectors
- Global regions, countries and organisation types
The last decade has seen remarkable innovation and development in the nucleotide sequencing field. Today, a number of powerful high–throughput sequencing technologies are available and are being used to address an increasingly diverse range of biological problems. The quantitative scale and efficiencies of next-generation sequencing platforms are also seeing unprecedented progress and growth in many areas of fundamental research. Also, dramatic reductions in the associated costs and the operational complexities of these techniques are opening up applications in areas that would have been unimaginable just a decade ago.
This report presents the findings of a new global study of nucleotide sequencing, which profiled the use of these techniques from the end-user’s perspective. This study, which evaluated end-users' current sequencing practices and three-year plans, investigated market growth, the competitive positions of global sequencing suppliers, sequencing laboratory location, preferred external Laboratories, sequencing methods, sequencing laboratory instruments, company suppliers, applications, clonal amplification, diseases, nucleotide types, software, sequencing performance, numbers of samples, disease Biomarkers, study samples, sample preparation, advantages and disadvantages, fields, participant roles, organisation type, experience, countries and regions.
Biopharm Reports' specialised market studies are designed to assist suppliers and developers to profile current and evolving market opportunities. All of our studies are carried out through specialist groups of experienced researchers and clinicians, and therefore findings are based on 'real world' market data. By providing new insights and a better understanding of end-user practices, needs and future plans, our studies assist suppliers to sell into these markets, and also support innovation and strategic planning. The following study areas were investigated:
Companies mentioned
More than 60 companies are mentioned in this report, namely 5-Prime, Affymetrix, Agencourt (Beckman Coulter), Agilent, AGRF, Ambion (Lifetech), AppliChem, Applied Biosystems, BD, Beckman, BGI, Bioline, Biomerieux, Biometra, Bio-Rad, Celera, Complete Genomics, DNA Technologies, Eppendorf, Eurofins, Exiqon, Fermentas, Fisher Scientific, Fluidigm, GE, Illumina, In-House, Integrated DNA Technologies (IDT), Invitrogen (Lifetech), Ion Torrent (LifeTech), Kapa Biosystems, Labgene, LGC Genomics, Li-Cor, Life technologies, Lucigen, Macherey-Nagel, Macrogen, Mallinckrodt Baker, Millennium Bioscience, MO BIO, Molecular Research Center, MP Biomedical, MWG Operon, New England Biolabs, Nugen, Orion Genomics, Oxford Nanopore, Pacific Biosciences, Perkin Elmer, Promega, Qiagen, Roche (454), Roche Diagnostics, Sangon Biotech, Seegene, Sequenom, Sigma-Aldrich, Solis BioDyne, Takara/Clontech, Tecan, Thermo Scientific, USB Corp and Zymo Research.
Sequencing Location: The locations of the laboratory where Sequencer's sequencing work are carried out, where the options considered were their own laboratory, and external laboratory or both own laboratory and external laboratory.
Preferred External Laboratories: Those sequencers who indicated that they contracted-out their sequencing activities to external laboratories were asked to indicate their preferred laboratories for this activity.
Growth: Based on recent trends in the numbers of sequencing studies carried out in their laboratories, end-users' estimates of by how much (% increase or % decrease) their laboratory use of sequencing has changed over the last three years. Also, based on current trends in the numbers of sequencing studies carried out in their laboratories, end-users' estimates of by how much (% increase or % decrease) they anticipate their laboratory use of sequencing will change over the next three years.
Sequencing methods: Sequencer’s main use of specific sequencing techniques, both currently and anticipated in three years from now, where the techniques considered (23 different methods) were 454 Pyrosequencing (Roche), Chain Termination Method (Sanger Sequencing), DArT Seq (Diversity Array Technology), DNA Nanoball Sequencing (Complete Genomics), DNA Nanopore Sequencing (Oxford Nanopore Technologies), Electron Microscopy-Based Sequencing (ZS Genetics), Gene Electronic Nano-Integrated Ultra-Sensitive Technology (Geneapsys), Ion Torrent (Thermo Fisher), Massively Parallel Signature Sequencing (Illumina), Microfluidic Sequencing (GnuBIO), Nanowire Biosensor Sequencing Technology (Quantumdx), RAD Sequencing (University Oregon/Floragenex), Sequencing by Hybridization (Affymetrix), Sequencing by Hybridization-Assisted Pore-Based sequencing (NABsys), Sequencing by mass spectrometry, Sequencing by Reversible-Hybridization (Complete Genomics), Sequencing by Synthesis (Illumina/Solexa), Shotgun Sequencing/Chain Termination (Sanger), Single Molecule Nanopore Sequencing (Noblegen Biosciences), Single Molecule Real-Time Sequencing (Pacific Biosciences), Single-molecule Semiconductor-Based Sequencing (Genia/Roche), SOLiD Sequencing (Applied Biosystems), Tunnelling Current DNA sequencing and any others.
Sequencing Instruments: Sequencer’s use of specific sequencing instruments, both currently and anticipated in three years from now, where the instruments considered (26 different systems) were Applied Biosystems: 3500 Genetic Analyzer, Applied Biosystems: 3500xL Genetic Analyzer, Applied Biosystems: 3730 DNA Analyzer, Applied Biosystems: 3730xl DNA Analyzer, Applied Biosystems: SOLiD Next-Generation System, BGI: BGISEQ-500 NGS System, Diversity Array Technology: Scanner (DArT Seq), Geneapsys: GENIUS, GnuBio: GnuBIO instrument, Illumina: HiSeq 2500, Illumina: HiSeq 3000/HiSeq 4000, Illumina: HiSeq X Five, Illumina: HiSeq X Ten, Illumina: MiniSeq, Illumina: MiSeq, Illumina: MiSeq FGx, Illumina: MiSeqDx, Illumina: NextSeq 500, Oxford Nanopore: GridION System, Oxford Nanopore: MinION, Oxford Nanopore: PromethION, Pacific Biosciences: PacBio RS II, Pacific Biosciences: Sequel System, Thermo Fisher: 3500 Genetic Analyser (Sanger), Thermo Fisher: Ion PGM System Ion PGM System, Thermo Fisher: Ion Proton System for NGS and any others.
External Laboratory Sequencing Service Providers: As part of this market study, external laboratories that provide nucleotide sequencing services to the end-users profiled, were also invesigated and are identified in this report.
Company Suppliers: End-users' current main suppliers of sequencing instruments, products or consumables, as well as those companies they anticipate will be supplying these products to their laboratories in three years from now, where 93 companies are considered, namely, 5-Prime, Abbott, Affymetrix, Agencourt (Beckman Coulter), Agilent, AGRF, Ambion (Lifetech), Anatech, Answer Choices, AppliChem, Applied Biosystems, BD, Beckman, BGI, Bioline, Biomerieux, Biometra, BioNanomatrix, Bioneer, Bionobile, Bionobile, Bio-Rad, Celera, Chemagen (PE), Complete Genomics, DNA Technologies, Eppendorf, Eurofins, EURx, Exiqon, Fermentas, Fisher Scientific, Fluidigm, FugiFilm, GE, GenDx, Halcyon Molecular, Illumina, In-House, Inqaba Biotechnology, Integrated DNA Technologies (IDT), Intelligent BioSystems, Invitek, Invitrogen (Lifetech), Ion Torrent (LifeTech), Kapa Biosystems, Labgene, LGC Genomics, Li-Cor, Life technologies, Lucigen, Macherey-Nagel, Macrogen, Mallinckrodt Baker, Millennium Bioscience, MO BIO, Molecular Research Center, MP Biomedical, MWG Operon, NABsys, New England Biolabs, Nexttec, Nippon Gene, Nugen, Orion Genomics, Oxford Nanopore, Pacific Biosciences, Panomics,
Perkin Elmer, Phoenix (Microarray), Primm Biotech, Promega, Qiagen, r-Biopharm, Roche, Roche (454), Roche Diagnostics, Roth, Sangon Biotech, Seegene, SeqLL, Sequenom, Sequiserve, Siemens, Sigma-Aldrich, Solis BioDyne, Stab Vida, Takara/Clontech, Tecan, Thermo Scientific, USB Corp, Vivantis, Zymo Research and any others.
Applications: End-users' current main applications of sequencing as well as the applications they anticipate using in three years from now, where the applications considered were Allele size detection, Aneuploidy and CNV analysis, Antibacterial resistance analysis, Antiviral resistance analysis, Bacterial typing, ChIP-Seq, Cloning, Complex populations, De Novo Sequencing, Detection, identification of bacteria, Detection, identification of viruses, Diverse gene polymorphisms, DNA barcoding, species identifications, DNA quantification, Epigenome characterization, Exome sequencing, Fragment analysis for epidemiological analysis, Full 16S sequencing for identification and phylogeny, Gene expression (mRNA), Gene mutations or alterations, Gene variants in disease, Genetic mapping, Genome Resequencing, Genotyping by Sequencing, Genotyping of microorganisms, Haplotypes, Immune diversity, Metagenomics, Methylation Sequencing, Microbial Sequencing, MicroRNA Studies, Microsatellites, Phylodynamic analyses, Rapid Diagnostic - Genetic Markers, Regulatory elements, Ribosomal DNA (rRNA) Studies, RNA Sequencing, Short Tandem Repeat Analysis, Single Nucleotide Polymorphisms, Single-Strand Conformation Polymorphism, Small insertions or deletions, Small Interfering RNA (siRNA) Studies, Small Nuclear RNA (snRNA) Studies, Small RNA and miRNA Sequencing, Targeted DNA sequencing, Targeted Resequencing, Tissue typing, Total RNA Sequencing (Transcriptome), Transfer RNA (tRNA) Studies, Ultra-Low-Input/Single-Cell RNA-Seq, Viral Typing, Whole-Genome Sequencing and any others.
Clonal Amplification: End-users' clonal amplifications methods used in their nucleotide sequencing, both currently and anticipated in three years, where the methods considered were Bridge PCR Amplification, Emulsion PCR Amplification, Rolling Circle Amplification and None (e.g. Single Molecule Sequencing).
Diseases: End-user's current sequencing activities, and those sequencing activities they anticipate in three years from now, relating to specific disease areas, namely Antimicrobial resistance, Arthritis, Asthma and allergy, Autoimmune Diseases, Bone Metabolism, Cancer, Cardiovascular, Central Nervous System, Dentistry, Dermatology, Endocrine, Gastrointestinal, Genetic diseases, Genito-Urinary System, Haematology, Hearing Loss, Immunodeficiency, Infections, Infertility, Inflammation, Liver disease, Metabolic Disorders, Musculoskeletal Disorders, None, Nutrition, Obstetrics and Gynaecology, Ophthalmology, Pain, Phytopathology, Psychiatry, Rare diseases, Reproduction, Respiratory, Sexually transmitted infections, Skin, Stem cells, Transplantation medicine, Vector borne disease, Virus diseases and any others.
Nucleotide Types: Main nucleic acid types currently sequenced, as well as those anticipated to be sequenced in three years from now, where the nucleic acids considered were Archaeal DNA, Bacterial DNA, Bacterial PCR amplicons, Bisulfite-converted DNA, cDNA, cell free miRNA, fungal DNA, Genomic DNA, ITS region, Metagenomic DNA, MicroRNA, Mitochondrial DNA, mRNA, Noncoding RNA, Nuclear DNA genes, Pathogen RNA/DNA, piRNA, Plant viral RNA or DNA, Plasma Cell Free DNA, Plasmid DNA, Prokaryotic small RNA, Protist DNA, Ribosomal RNA (rRNA), Small interfering RNA (siRNA), Small nuclear RNA (snRNA), Total RNA, Transfer RNA (tRNA), Tumour Cell DNA, Viral DNA, Viral PCR amplicons, Viral RNA and any others.
Software: Sequencers main software programs used for their nucleotide sequencing activities and those considered (n = 387) were ABA (Raphaelet al.), ABySS (Simpson et al.), ACANA (Huang et al.), ACT (Sanger), Alamut (Interactive Biosoftware), ALE (Blandy et al.), AlignMe (Stamm et al.), ALLPATHS (Broad Institute), Alta-cyclic (Omictools), AMAP (Schwartz et al.), AnnHyb (MyBiosoftware), Annovar (Open Bioinformatics), anon. (Powell et al.), Answer Choices, Artemis (Sanger), Augustus (Gottingen), AVID (Vista), BAliBASE (Thompson et al.), BAli-Phy (Redelings et al.), BarraCUDA (GPL), Base-By-Base (Brodie et al.), BBMap (Source Forge), Beast (Drummond et al.), Belvu (Sanger), BFAST (GPL), BigBWA (Omictools), Bioconductor (Aboyoun et al.), BioEdit (Ibis), BioLinux (EON), Biomart (Ensembl), BioNumerics (Applied Maths), BioPerl dpAlign (Chan et al.), Biopieces (Biostars), BisMark (Babraham), BLAST (Altschul et al.), BLASTN (NCBI), BLASTZ,LASTZ (Schwartz et al.), BLAT (Non-Commercial Academic), BLOCKS (Molbio-Tools), Bowtie (Artistic License), BS-Seq (UCLA), Bustard (Illumina), BWA (GPL), BWA-PSSM (Bio-BWA), Cap3 (Genome), Casava (Illumina), CASHX (Non-Commercial Academic), CEQ (Beckman et al.), CHAOS/DIALIGN (Brudno et al.), ChIP-Seq (DNASTar), Chromas (Technelysium), Clarity (Genologics), CLC Genomic Workbench (CLCBio), Clone Manager (CLCBio), Cloudburst (Artistic License), ClustalW (Thompson et al.), CNVnator (Omictools), CNV-Seq (Chao et al.), CodonCode Aligner (Richterich et al.), Compass (Sadreyev, et al.), Contig Express (Contig), CS-BLAST (Angermueller et al.), CUDA-EC (Omictools), CUDAlign (Source Forge), CUDA-MEME (MyBiosoftware), CUDASW++ (Liu et al.), Cufflinks (Cole-trapnell), CUSHAW (GPL), CUSHAW2 (GPL), CUSHAW2-GPU (GPL), CUSHAW3 (Source Forge), Custom Designed (In-House), Dalliance (Omictools), dbSNP (Open Source), DECIPHER (DecipherProject), DESeq (Bioconductor), DIALIGN-TX and DIALIGN-T (Subramanian et al.), DIAMOND (GitHub), DNA Alignment (Roehl et al.), DNA Baser Sequence Assembler (Heracle BioSoft), DNADot (Bowen et al.), DNAsp (UBEdu), DNASTAR (DNAStar), DOTLET (Pagni et al.), dpAlign (BioPerl), drFAST (BSD), EagleView (Boston College), Edena (Hernandez ), EDNA (Salama et al.), ELAND (Illumina), EMBL-EBI (EBI Ac), eMOTIF (Stanford), Ensemble (Ensembl), ERANGE (Wold Lab), ERNE (GPL), EULER-SR (Chaisson ), Excel (Open Source), Exonerate (Guy St C Slater et al.), ExpressionSuite (Thermo Fisher), FASTA (Faster Biotech), Fastpcr (PrimerDigital), FastQC (Babraham), fastseq (Helical), fastx-tools (Hannon), FEAST (Hudek et al.), FindPeaks (Bainbridge et al.), FMM (Open Source), FreeBayes (Omictools), FSA (Bradley et al.), Galaxy (Galaxy), GapMis (Frousios et al.), GASSST (Omictools), GATK (Broad Institute), GEM (Non-Commercial Academic), GenAlex (BiologyAssets), Genalice MAP (Genalice), GenDB (Open Source), Gene Construction Kit (Textco), Gene Mapper (ABI), Gene tex (Genetex), GeneInsight (Geneinsight), Geneious (Drummond et al.), Geneious Assembler (Geneious), GeneMapper® Software (ABI), Genologics (Illumina), Genomatix (Genomatix), Genome Browser (UCSC), Genome Compiler (Genome Compiler), GenomeMapper (1001 Genomes project), GenomeStudio Software (Illumina), Genomics Workbench (CLCBio), Genoogle (Genoogle), Genotyper (ABI), GenSearch (Phenosystems), GensearchNGS (Omictools), Geospiza (Geospiza et al.), GGSEARCH, GLSEARCH (Pearson et al.), Gibbs motif sampler (Omictools), Glimmer (CBCD), GLProbs (Omictools), GMAP and GSNAP (Non-Commercial Academic), G-Mo.R-Se (CNS, France), GNUMAP (Omictools), G-PAS (Frohmberg et al.), GS Amplicon Variant Analyzer (Roche), HapCompass (Omictools), HGMD (Biobase), HHpred / HHsearch (Soding et al.), HiSeq Software (Illumina), HIVE-hexagon (Hive), HMMER (Durbin et al.), HMMTOP (SACS), HOMSTRAD (Mizuguchi et al.), Htseq (Huber et al.), HyPhy (Hyphy et al.), Ibis (Ibis), IDF (CSUni), IGV (Broad Institute), IMEX (Omictools), IMGT (IMGT), Infernal (Eddy), Ingenuity (Ingenuity), In-House (In-House), Ion Reporter (Thermo Fisher), Ion torrent (Thermo Fisher), iSAAC (Non-Commercial Academic), I-sites (Open Source), JAligner (Moustafa et al.), Jalview (Jalview), JCoils (CHEmbnet), KSync (Chivian et al.), Kalign (Lassmann et al.), KLAST (CLCBio), Kodon (Applied Maths), LALIGN (Pearson et al.), Lasergene (DNAStar), LAST (GPL), LASTZ (NCBI), LookSeq (Sanger), MACS (Zhang et al. ), MacVector (MacVector), MAFFT (Katoh et al.), Mage Platform (Genoscope), mAlign (Powell et al. ), Manattee (Manattee), MapNext (Sun-Yat Sen Univ), MapView (Sun-Yat Sen Univ), MAQ (GPL), MARNA (Siebert et al.), Matcher (Longden et al.), Mauve (Darlinglab), MAVID (Bray et al.), MCALIGN2 (Wang et al.), MEGA (Megasoft), MEME/MAST (Meme), MERCI (Bioinfo), Metacore (Omictools), MG RAST (Metagenomics), MGA (Omictools), Mira (Omictools), MIRA2 - MIRA (Source Forge), MirCheck (Mybiosoftware), Mirdeep2 (MDC Berlin), miREvo (Omictools), MiSeq (Illumina), MiSeq Software (Illumina), MOM (CS.CMU), MOSAIK (Stromberg et al. ), Mothur (Mothur), MPscan (Omictools), MrBayes (MrBayes), mrFAST and mrsFAST (BSD), MSA (Lipman et al.), MSAProbs (Liu et al.), MSeqDR (Open Source), Mulan (Mulan), MULTALIN (Corpet et al.), Multi-LAGAN (Brudno et al.), Multiz (Mybiosoftware), MUMmer (Kurtz et al.), MUSCLE (Edgar et al.), Mutation Surveyor (Softgenetics), mVista (Genome), MyRAST (Mybiosoftware), NCBI (Open Source), Needle (Bleasby et al.), NETGLYC (CBS), NetPrimer (PremierBiosoft), Newbler (Roche), NextGENe (Softgenetics), NextGenMap (Omictools), Ngila (Cartwright et al.), NISC (NIH), Novoalign & NovoalignCS (Non-Commercial Academic), NW-align (Zhang et al.), Omixon (Omixon), Opal (Wheeler et al.), Oxbench (Raghava et al.), PAL_finder (Source Forge), PALMapper (GPL), Pandaseq (Github), Panther (Omictools), Parasail (BMC), Partek (Partek), Pasa (Pasa), PASS (CRIBI), Path (Girdea et al.), PathSeq (Broad Institute), PatternHunter (Ma et al.), PAUP (Evolution), PeakSeq (Rozowsk et al.), Pecan (Paten et al.), PerM (GPL), PFAM (Sanger), PHI-Blast (NCBI), Phylo (McGill Bioinformatics), Phylogeny (Evolution), Phyloscan (NCBI), phyML (ATGC), Picard (Broad Institute), PicXAA (Omictools), PLAST-ncRNA (NCBI), PMS (Open Source), POA (Lee et al.), PolyBayesShort (Boston College), Polyphen (Harvard), Praline (Heringa et al.), PRATT (EBI Ac), PREFAB (Edgar et al.), Primer 3 (PremierBiosoft), PRIMEX (Open Source), Prism (ABI), ProbA (also propA) (Muckstein et al), Probalign (Roshan et al.), ProbCons (Do et al.), Prodigal (Omictools), PROMALS3D (Pei et al.), Proseq (Biosoft), PRRN/PRRP (Totoki et al), PSAlign (Sze et al.), PSI-BLAST (Altschul et al. ), PSI-Search (Li et al.), PyMOL (DeLano et al.), PyroBayes (Boston College), Python (DigitalBiol), QIIME (QIIME), Qpalma (De Bona et al. ), QuEST (Stanford), R (Open Source), RAST (Molbiotools), Ray (Denovo), RazerS (LGPL), RDP (NCBI), REAL, cREAL (GPL), REPuter (Kurtz et al.), Responses, Responses, RevTrans (Wernersson et al.), RMAP (GPL), rNA (GPL), RNASAT (Stanford), Rolexa (Bioconductor), RTG Investigator (Non-Commercial Academic), SABERTOOTH (Teichert et al.), SABmark (Van Walle et al.), SAGA (Notredame et al.), SAM (Krogh et al.), Satsuma (Grabherr et al.), ScalaBLAST (Oehmen et al.), ScanProsite (Prosite), Se-Al (Rambaut et al.), Seaview (Mybiosoftware), Segemehl (Non-Commercial Academic), SEQALN (Waterman et al.), SEQAN (Rausch et al.), SeqMan (DNAStar), SeqMap (Jiang et al.), SeqScape (Thermo Fisher), Sequence Scanner Software (ABI), Sequences Studio (Meskauskas et al.), Sequencher (Gene Codes Corp), Sequencing Analysis Software (ABI), Sequencing Analysis Viewer (Illumina), Sequerome (Bioinformatics.org), Sequilab (Lifescisoft), Serial Cloner (SerialBasics), SHARCGS (Dohm et al.), SHORE (1001 Genomes project), Shrec (Omictools), SHRiMP (Brudno et al.), Shuffle-LAGAN (Stanford), SIBsim4 / Sim4 (NEBC), SIM, GAP, NAP, LAP (Huang et al.), SISSRs (Jothi et al.), Slider (BCGSC), SlimSearch (EdwardsLab), SMART (Letunic et al.), SOAP, SOAP2, SOAP3 and SOAP3-dp (GPL), SOCS (Ondov et al.), SOLiD™ Software (ABI), SPA (Shen et al), SPAdes (Open Source), Splign (Open Source), SSAHA and SSAHA2 (Non-Commercial Academic), SSAKE (Omictools), SSEARCH (Pearson et al.), Staden (Source Forge), Stampy (Non-Commercial Academic), StatAlign (Novak et al.), Stemloc (Holmes et al.), SToRM (Omictools), stretcher (Longden et al.), Subread and Subjunc (GPL), SureCall (Agilent), SWAPHI (Open Source), SWAPHI-LS (Open Source), SWIFT suit (Rasmussen et al.), SWIPE (GNU), SXOligoSearch (Synamatix), Syngene (GeneTools), Tablet (Omictools), Taipan (Non-Commercial Academic), T-Coffee (Notredame et al.), TEIRESIAS (IBM), TopHat (Univ's Maryland/California ), Torrent (Thermo Fisher), tranalign (Williams et al.), Trinity (Strozzi et al.), UCHIME (Mothur), UCLUST (NEBC), UGENE (GPL), USEARCH (Drive5), VarScan (Source Forge), VCAKE (Omictools), Vector NTI (Thermo Fisher), VectorFriends (BioFriends team), VelociMapper (Omictools), Velvet (Zerbino et al), Vmatch (VMatch ), water (Bleasby et al.), wordmatch (Longden et al.), XMatchView (Warren et al. ), XpressAlign (Non-Commercial Academic), YASS (Noe et al), Zenbu (Omictools), ZOOM (Omictools) and any Others.
Sequencing Performance: Five areas of the performance of end-users' sequencing activities were investigated namely read length (bp) that they typically achieve in your sequencing work, the accuracy (%, single read, not consensus) that they believe they achieve in their work, the reads per run (in millions of bases) that they typically achieve in their work, the typical time per run (minutes, hours, days, weeks or months) in their sequencing work and the sequencing costs in terms of US$ per 1 million bases.
Numbers of samples: Sequencers estimates of the number of study samples they sequence in their laboratory, where the options were <1; 1; 1 to 2; 2 to 3; 3 to 4; 4 to 5; 5 to 7; 7 to 10; 10 to 15; 15 to 25; 25 to 40; 40 to 60; 60 to 100; 100 to 150; 150 to 200; 200 to 250 or 250.
Disease Biomarkers: Sequencers were asked if they use sequencing to research, discover or measure disease biomarkers, where the options were yes or no. Those who answered yes to this question were asked to indicate indicate which disease biomarkers they study in their sequencing work. These included Absolute DNA quantification, Alternative spliced variants, Bacteria detection, DNA methylation, Gene copy number, Gene expression, Gene mutations/polymorphisms, Haplotypes, microRNA, Protein mRNA quantification, Single nucleotide polymorphisms (SNPs), Small interfering RNA, Small nuclear RNA, SSRs or TRs, Tissue typing, Virus detection or any others.
Study samples: Sequencers were asked to indicate the main study samples in their sequencing activities where the options were Algal, Animal tissues, Archaeal cultures, Bacterial cultures, Bone, Cell isolates, Cells, Cerebrospinal fluid, Cultures, Dried blood, Embryos, Environmental samples, Faeces/Stools, Fermented foods, Foodstuffs, Fungal material, Genetic material, Human tissues, Insect material, In-vitro solutions, Isolated viruses, Marine, Marine invertebrates, Paraffin embedded tissue, Phage material, Plant material, Plasma, Protozoa, Respiratory fluids, Saliva, Semen, Serum, Soil, Swabs, Teeth, Urine, Venom, Water, Whole blood or any others.
Sample Preparation: Sequencers were asked to indicate the main sample preparation method(s) that they use in their sequencing activities, where the methods considered were solution-Phase Methods; Automated Solution-Phase Methods; Solid-Phase Methods; Automated Solid-Phase Methods or others. Sequencers were also asked to indicate if they used kit-based sample preparation products in your nucleotide sequencing activities. Those who did were invited to indicate their preferred suppliers.
Advantages and disadvantages: Sequencers were asked to indicate that they considered to be the main advantages and disadvantages of their most commonly used nucleotide sequencing techniques.
Fields: End-users' field or sector relating to their use of sequencing, including Bacteriology, Bioinformatics, Blood groups, Blood products, Cell research, Clinical research, Clinical trials, Conservation Genetics, Diagnostic screening, Diagnostics, Diagnostics research, Disease biomarkers, Disease research, Drug R&D, Drug targets, Environmental microbiology, Environmental tests, Evolutionary biology, Food monitoring, Forensics Genetics, Fundamental research, Genomics, Histology, HLA-Typing for transplantation, Immunology, Laboratory surveillance, Metagenomics, Microbiology, Mitochondrial DNA, Molecular Ecology, Molecular epidemiology, Molecular Systematics, Natural products, Parasitology, Paternity Testing, Phylogenetics, Plant Breeding, Plant Evolution, Plant Sciences, Population genetics, Preclinical research, Proteomics, Responses, Soil ecology, Taxonomy, Treatment monitoring, Virology and other.
Role: End-user's main role relating to their use of nucleotide sequencing, where the options were Laboratory Scientist, Physician or Clinician, Laboratory or Clinical Manager, Veterinarian and Other.
Organisation Type: End-users organisation type, where the options were Clinic, Government Organisation, Hospital, Large International Company, Medium Sized Company, Research Institute, Small Company, Teaching Hospital, University, Veterinary Organisation or other.
Experience: End-users' years of experience using nucleotide sequencing.
Job Title: End-user's job title.
Countries and Regions: End-users' countries and global regions; Asia, North America, South America, Africa (Sub-Saharan), Central America/Caribbean, Australia, New Zealand and Oceania and Middle East/North Africa/and Greater Arabia.
Participants: Names, organisation name and business email address.
1. INTRODUCTION
1.1 Introduction
1.2 Background
1.3 Market Questions
2. PARTICIPANTS
2.1 Participants
2.2 Global Regions
2.3 Countries
2.4 Job Titles
2.5 Experience
2.6 Organisation Types
2.7 Roles
2.8 Main Purpose
2.9 Discussion
3. FIELDS
3.1 Fields
3.2 2016 Study
3.3 2013 Study
3.4 Discussion
4. SEQUENCING LABORATORY LOCATION
4.1 Location
4.2 Laboratory Location
4.3 Preferred external Laboratories
4.4 Discussion
5. DISEASES
5.1 Diseases
5.2 2016 Study
5.3 2015 Study
5.4 Discussion
6. SEQUENCING METHODS
6.1 Methods
6.2 2016 Study
6.3 2015 Study
6.4. Discussion
7. SEQUENCING INSTRUMENTS
7.1 Instruments
7.2 Findings
7.3 Discussion
8. ADVANTAGES AND DISADVANTAGES
8.1 Advantages and Disadvantages
8.2 2016 Study
8.3 2015 Study
8.4 Discussion
9. SEQUENCING APPLICATIONS
9.1. Sequencing Applications
9.2 2016 Study
9.3 2015 Study
9.4. Discussion
10. CLONAL AMPLIFICATION
10.1 Clonal Amplification
10.2 Current Amplification
10.3 Future Amplification
11. SEQUENCING SOFTWARE
11.1 Sequencing Software
11.2 2016 Study
11.3 2015 Study
11.4. Discussion
12. SEQUENCING PERFORMANCE
12.1 Sequencing Performance
12.2 Read Lengths
12.3 Sequencing Accuracy
12.4 Reads Per Run
12.5 Sequencing Costs
12.6 Discussion
13. NUCLEIC ACID TYPES
13.1 Nucleotide Types
13.2 2016 Study
13.3 2015 Study
13.4 Biomarkers Types
13.5 Preferred Kit Suppliers
13.6 Discussion
14. TRENDS AND GROWTH
14.1 Sequencing Growth Trends
14.2 2016 Study
14.3 2015 Study
14.4 Discussion
15. SUPPLIERS
15.1 Suppliers
15.2 2016 Study
15.3 2015 Study
15.4 Discussion
16. STUDY SAMPLES
16.1 Study Samples
16.2 2016 Study
16.3 2015 Study
16.4 Discussion
17. SAMPLE PREPARATION
17.0 Sample Preparation
17.1 This Chapter
17.2 2016 Study
17.3 2015 Study
18. SAMPLE PREPARATION KITS
18.1 Sample Preparation Kits
18.2 Kits
19. DISEASE BIOMARKERS
19.1 Biomarkers
19.2 2016 Study
19.3 2015 Study
19.4. Discussion
20. COSTS AND THROUGHPUT
20.1 Sample Throughput and Costs
20.2 Sample Throughput
20.3 Sequencing Costs
20.4 Discussion
21. DISCUSSION (P.180)
21.1 Discussion
1.1 Introduction
1.2 Background
1.3 Market Questions
2. PARTICIPANTS
2.1 Participants
2.2 Global Regions
2.3 Countries
2.4 Job Titles
2.5 Experience
2.6 Organisation Types
2.7 Roles
2.8 Main Purpose
2.9 Discussion
3. FIELDS
3.1 Fields
3.2 2016 Study
3.3 2013 Study
3.4 Discussion
4. SEQUENCING LABORATORY LOCATION
4.1 Location
4.2 Laboratory Location
4.3 Preferred external Laboratories
4.4 Discussion
5. DISEASES
5.1 Diseases
5.2 2016 Study
5.3 2015 Study
5.4 Discussion
6. SEQUENCING METHODS
6.1 Methods
6.2 2016 Study
6.3 2015 Study
6.4. Discussion
7. SEQUENCING INSTRUMENTS
7.1 Instruments
7.2 Findings
7.3 Discussion
8. ADVANTAGES AND DISADVANTAGES
8.1 Advantages and Disadvantages
8.2 2016 Study
8.3 2015 Study
8.4 Discussion
9. SEQUENCING APPLICATIONS
9.1. Sequencing Applications
9.2 2016 Study
9.3 2015 Study
9.4. Discussion
10. CLONAL AMPLIFICATION
10.1 Clonal Amplification
10.2 Current Amplification
10.3 Future Amplification
11. SEQUENCING SOFTWARE
11.1 Sequencing Software
11.2 2016 Study
11.3 2015 Study
11.4. Discussion
12. SEQUENCING PERFORMANCE
12.1 Sequencing Performance
12.2 Read Lengths
12.3 Sequencing Accuracy
12.4 Reads Per Run
12.5 Sequencing Costs
12.6 Discussion
13. NUCLEIC ACID TYPES
13.1 Nucleotide Types
13.2 2016 Study
13.3 2015 Study
13.4 Biomarkers Types
13.5 Preferred Kit Suppliers
13.6 Discussion
14. TRENDS AND GROWTH
14.1 Sequencing Growth Trends
14.2 2016 Study
14.3 2015 Study
14.4 Discussion
15. SUPPLIERS
15.1 Suppliers
15.2 2016 Study
15.3 2015 Study
15.4 Discussion
16. STUDY SAMPLES
16.1 Study Samples
16.2 2016 Study
16.3 2015 Study
16.4 Discussion
17. SAMPLE PREPARATION
17.0 Sample Preparation
17.1 This Chapter
17.2 2016 Study
17.3 2015 Study
18. SAMPLE PREPARATION KITS
18.1 Sample Preparation Kits
18.2 Kits
19. DISEASE BIOMARKERS
19.1 Biomarkers
19.2 2016 Study
19.3 2015 Study
19.4. Discussion
20. COSTS AND THROUGHPUT
20.1 Sample Throughput and Costs
20.2 Sample Throughput
20.3 Sequencing Costs
20.4 Discussion
21. DISCUSSION (P.180)
21.1 Discussion
FIGURES
Figure 2.1. Global regions of participants in SEQ 2016
Figure 2.2. Global regions of participants in SEQ 2015
Figure 2.3. Top ten countries of participants in SEQ 2016
Figure 2.4. Top ten countries of participants in SEQ 2015
Figure 2.5. Top ten job titles of participants in SEQ 2016
Figure 2.6. Top ten job titles of participants in SEQ 2015
Figure 2.7. Top ten experience levels in DNA and RNA sequencing, of SEQ 2016 participants
Figure 2.8. Top ten experience levels of participants in SEQ2015
Figure 2.9. Top ten organisation types of participants in SEQ 2016
Figure 2.10. Organisations types of participants in SEQ 2015
Figure 2.11. Roles of participants in SEQ 2016
Figure 2.12. Roles of participants in SEQ2015
Figure 2.13. Top ten main purposes of sequencing activities of participants in SEQ2015
Figure 3.1. Top ten fields of work relating to
Figure 3.2. Top ten fields of participants in SEQ2015
Figure 4.1. Laboratory locations of DNA/RNA sequencing of SEQ 2016 participants
Figure 4.2. Laboratory locations of DNA/RNA sequencing of SEQ 2016 participants
Figure 5.1. Top ten current disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Figure 5.2. Top ten future anticipated disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Figure 5.3. Top ten current disease areas relating to sequencing, of participants in SEQ2015
Figure 5.4. Top ten future disease areas relating to sequencing, of participants in SEQ2015
Figure 6.1. Top ten current sequencing methods of SEQ 2016 participants
Figure 6.2. Top ten future anticipated sequencing methods of SEQ 2016 participants
Figure 6.3. Top ten current sequencing techniques, of participants in SEQ2015
Figure 6.4. Top ten future sequencing techniques, of participants in SEQ2015
Figure 7.1. Top ten current sequencing instruments used by SEQ 2016 participants
Figure 7.2. Top ten future anticipated sequencing instruments of SEQ 2016 participants
Figure 8.1. Top ten advantages of the DNA sequencing techniques, of participants in SEQ2015
Figure 8.2. Top ten disadvantages of the DNA sequencing techniques, of participants in SEQ2015
Figure 9.1. Top ten current sequencing applications of SEQ 2016 participants
Figure 9.2. Top ten future sequencing applications of SEQ 2016 participants
Figure 9.3. Top ten current applications of sequencing activities, of participants in SEQ2015
Figure 9.4. Top ten future applications of sequencing activities, of participants in SEQ 2015
Figure 10.1. Current clonal amplification methods of SEQ 2016 participants
Figure 10.2. Future clonal amplification methods of SEQ 2016 participants
Figure 11.1. Top sequencing software (A – M) used by SEQ 2016 participants
Figure 11.2. Top sequencing software (A – M) used by SEQ 2016 participants
Figure 11.3. Software used in DNA sequencing, of participants in SEQ2015
Figure 13.1. Top ten current nucleotide types sequenced by SEQ 2016 participants
Figure 13.2. Top ten future anticipated nucleotide types to be sequenced by SEQ 2016 participants
Figure 13.3. Top ten current nucleic acids types in their sequencing activities, of participants in SEQ2015
Figure 13.4. Top ten future nucleic acids types in their sequencing activities, of participants in SEQ2015
Figure 14.1. Top ten recent sequencing growth trends of SEQ 2016 participants
Figure 14.2. Top ten future anticipated sequencing growth trends of SEQ 2016 participants
Figure 14.3. Top ten recent trend levels in their sequencing activities, of participants in SEQ2015
Figure 14.4. Top ten future anticipated trend levels in their sequencing activities, of participants in SEQ2015
Figure 15.1. Top ten current sequencing suppliers of SEQ 2016 participants
Figure 15.2. Top ten future sequencing suppliers of SEQ 2016 participants
Figure 15.3. Top ten current suppliers in their sequencing activities, of participants in SEQ2015
Figure 15.4. Top ten future anticipated suppliers in their sequencing activities, of participants in SEQ 2015
Figure 16.1. Top ten samples sequenced by SEQ 2016 participants
Figure 16.2. Top ten study samples in their sequencing activities, of participants in SEQ2015
Figure 17.1. Top ten sequencing sample preparation methods used by SEQ 2016 participants
Figure 17.2. Main sample preparation methods used in their sequencing activities, of participants in SEQ2015
Figure 18.1. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Figure 18.2. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2015
Figure 18.2. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2015
Figure 18.3. Preferred suppliers of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Figure 18.4. Preferred suppliers of sample preparation kits in their sequencing activities, of participants in SEQ 2015
Figure 19.1. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Figure 19.2. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Figure 19.3. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Figure 19.4. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Figure 20.1. Top ten per-sample sequencing cost levels in their sequencing activities, of participants in SEQ2015
Figure 2.1. Global regions of participants in SEQ 2016
Figure 2.2. Global regions of participants in SEQ 2015
Figure 2.3. Top ten countries of participants in SEQ 2016
Figure 2.4. Top ten countries of participants in SEQ 2015
Figure 2.5. Top ten job titles of participants in SEQ 2016
Figure 2.6. Top ten job titles of participants in SEQ 2015
Figure 2.7. Top ten experience levels in DNA and RNA sequencing, of SEQ 2016 participants
Figure 2.8. Top ten experience levels of participants in SEQ2015
Figure 2.9. Top ten organisation types of participants in SEQ 2016
Figure 2.10. Organisations types of participants in SEQ 2015
Figure 2.11. Roles of participants in SEQ 2016
Figure 2.12. Roles of participants in SEQ2015
Figure 2.13. Top ten main purposes of sequencing activities of participants in SEQ2015
Figure 3.1. Top ten fields of work relating to
Figure 3.2. Top ten fields of participants in SEQ2015
Figure 4.1. Laboratory locations of DNA/RNA sequencing of SEQ 2016 participants
Figure 4.2. Laboratory locations of DNA/RNA sequencing of SEQ 2016 participants
Figure 5.1. Top ten current disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Figure 5.2. Top ten future anticipated disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Figure 5.3. Top ten current disease areas relating to sequencing, of participants in SEQ2015
Figure 5.4. Top ten future disease areas relating to sequencing, of participants in SEQ2015
Figure 6.1. Top ten current sequencing methods of SEQ 2016 participants
Figure 6.2. Top ten future anticipated sequencing methods of SEQ 2016 participants
Figure 6.3. Top ten current sequencing techniques, of participants in SEQ2015
Figure 6.4. Top ten future sequencing techniques, of participants in SEQ2015
Figure 7.1. Top ten current sequencing instruments used by SEQ 2016 participants
Figure 7.2. Top ten future anticipated sequencing instruments of SEQ 2016 participants
Figure 8.1. Top ten advantages of the DNA sequencing techniques, of participants in SEQ2015
Figure 8.2. Top ten disadvantages of the DNA sequencing techniques, of participants in SEQ2015
Figure 9.1. Top ten current sequencing applications of SEQ 2016 participants
Figure 9.2. Top ten future sequencing applications of SEQ 2016 participants
Figure 9.3. Top ten current applications of sequencing activities, of participants in SEQ2015
Figure 9.4. Top ten future applications of sequencing activities, of participants in SEQ 2015
Figure 10.1. Current clonal amplification methods of SEQ 2016 participants
Figure 10.2. Future clonal amplification methods of SEQ 2016 participants
Figure 11.1. Top sequencing software (A – M) used by SEQ 2016 participants
Figure 11.2. Top sequencing software (A – M) used by SEQ 2016 participants
Figure 11.3. Software used in DNA sequencing, of participants in SEQ2015
Figure 13.1. Top ten current nucleotide types sequenced by SEQ 2016 participants
Figure 13.2. Top ten future anticipated nucleotide types to be sequenced by SEQ 2016 participants
Figure 13.3. Top ten current nucleic acids types in their sequencing activities, of participants in SEQ2015
Figure 13.4. Top ten future nucleic acids types in their sequencing activities, of participants in SEQ2015
Figure 14.1. Top ten recent sequencing growth trends of SEQ 2016 participants
Figure 14.2. Top ten future anticipated sequencing growth trends of SEQ 2016 participants
Figure 14.3. Top ten recent trend levels in their sequencing activities, of participants in SEQ2015
Figure 14.4. Top ten future anticipated trend levels in their sequencing activities, of participants in SEQ2015
Figure 15.1. Top ten current sequencing suppliers of SEQ 2016 participants
Figure 15.2. Top ten future sequencing suppliers of SEQ 2016 participants
Figure 15.3. Top ten current suppliers in their sequencing activities, of participants in SEQ2015
Figure 15.4. Top ten future anticipated suppliers in their sequencing activities, of participants in SEQ 2015
Figure 16.1. Top ten samples sequenced by SEQ 2016 participants
Figure 16.2. Top ten study samples in their sequencing activities, of participants in SEQ2015
Figure 17.1. Top ten sequencing sample preparation methods used by SEQ 2016 participants
Figure 17.2. Main sample preparation methods used in their sequencing activities, of participants in SEQ2015
Figure 18.1. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Figure 18.2. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2015
Figure 18.2. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2015
Figure 18.3. Preferred suppliers of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Figure 18.4. Preferred suppliers of sample preparation kits in their sequencing activities, of participants in SEQ 2015
Figure 19.1. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Figure 19.2. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Figure 19.3. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Figure 19.4. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Figure 20.1. Top ten per-sample sequencing cost levels in their sequencing activities, of participants in SEQ2015
TABLES
Table 2.1. Global regions of participants in SEQ 2016
Table 2.2. Global regions of participants in SEQ2015
Table 2.3. Countries of participants in SEQ 2016
Table 2.4. Countries of participants in SEQ2015
Table 2.5. Job titles of participants in SEQ 2016
Table 2.6. Job titles of participants in SEQ2015
Table 2.7. Experience levels in DNA and RNA sequencing, of SEQ 2016 participants
Table 2.8. Experience levels of participants in SEQ2015
Table 2.9. Organisation types of participants in SEQ 2016
Table 2.10. Organisations types of participants in SEQ2015
Table 2.11. Roles of participants in SEQ 2016
Table 2.12. Roles of participants in SEQ 2015
Table 2.13. Main purposes of sequencing activities of participants in SEQ2015
Table 3.1. Fields of work relating to DNA and RNA sequencing of SEQ 2016 participants
Table 3.2. Fields of participants in SEQ 2015
Table 4.1. Laboratory locations of DNA/RNA sequencing of SEQ 2016 participants
Table 5.1. Current disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Table 5.2. Anticipated future disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Table 5.3. Current disease areas relating to sequencing, of participants in SEQ2015
Table 5.4. Future disease areas relating to sequencing, of participants in SEQ2015
Table 6.1. Current sequencing methods of SEQ 2016 participants
Table 6.2. Future anticipated sequencing methods of SEQ 2016 participants
Table 6.3. Current sequencing techniques, of participants in SEQ2015
Table 6.4. Future sequencing techniques, of participants in SEQ2015
Table 7.1. Current sequencing instruments used by SEQ 2016 participants
Table 7.2. Future anticipated sequencing instruments of SEQ 2016 participants
Table 8.1. Advantages cited by 2016 end-users of the sequencing techniques they use
Table 8.2. Disadvantages cited by 2016 end-users of the sequencing techniques they use
Table 8.3. Top ten advantages of the DNA sequencing techniques, of participants in SEQ 2015
Table 8.4. Top ten disadvantages of the DNA sequencing techniques, of participants in SEQ2015
Table 9.1. Current sequencing applications of SEQ 2016 participants
Table 9.2. Future anticipated sequencing applications of SEQ 2016 participants
Table 9.3. Current applications of sequencing activities, of participants in SEQ2015
Table 9.4. Future applications of sequencing activities, of participants in SEQ 2015
Table 10.1. Current clonal amplification methods of SEQ 2016 participants
Table 10.2. Future clonal amplification methods of SEQ 2016 participants
Table 11.1. Top sequencing software (A – M) used by SEQ 2016 participants
Table 11.2. Top sequencing software (M – Z) used by SEQ 2016 participants
Table 11.3. Software used in DNA sequencing, of participants in SEQ2015
Table 13.1. Current nucleotide types sequenced by SEQ 2016 participants
Table 13.2. Top ten future anticipated nucleotide types to be sequenced by SEQ 2016 participants
Table 13.3. Current nucleic acids types in their sequencing activities, of participants in SEQ2015
Table 13.4. Future nucleic acids types in their sequencing activities, of participants in SEQ2015
Table 14.1. Recent sequencing growth trends of suppliers of SEQ 2016 participants
Table 14.2. Future anticipated sequencing growth trends of SEQ 2016 participants
Table 14.3. Recent trend levels in their sequencing activities, of participants in SEQ2015
Table 14.4. Future anticipated trend levels in their sequencing activities, of participants in SEQ2015
Table 15.1. Current sequencing suppliers of SEQ 2016 participants
Table 15.2. Future sequencing suppliers of SEQ 2016 participants
Table 15.3. Current suppliers in their sequencing activities, of participants in SEQ2015
Table 15.4 Future anticipated suppliers in their sequencing activities, of participants in SEQ 2015
Table 16.1. Samples sequenced sequenced by SEQ 2016 participants
Table 16.2. Study samples in their sequencing activities, of participants in SEQ2015
Table 17.1. Sequencing sample preparation methods used by SEQ 2016 participants
Table 17.2. Main sample preparation methods used in their sequencing activities, of participants in SEQ2015
Table 18.1. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Table 18.3. Preferred suppliers of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Table 19.1. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Table 19.2. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Table 19.3. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Table 19.4. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Table 20.1. Sample throughput levels in DNA and RNA sequencing, indicated by end-users in SEQ 2016
Table 20.2. Sample throughput levels in DNA and RNA sequencing, indicated by end-users in SEQ 2015
Table 20.3. Per-sample sequencing cost levels in their DNA sequencing activities, of participants in SEQ2015
Table 2.1. Global regions of participants in SEQ 2016
Table 2.2. Global regions of participants in SEQ2015
Table 2.3. Countries of participants in SEQ 2016
Table 2.4. Countries of participants in SEQ2015
Table 2.5. Job titles of participants in SEQ 2016
Table 2.6. Job titles of participants in SEQ2015
Table 2.7. Experience levels in DNA and RNA sequencing, of SEQ 2016 participants
Table 2.8. Experience levels of participants in SEQ2015
Table 2.9. Organisation types of participants in SEQ 2016
Table 2.10. Organisations types of participants in SEQ2015
Table 2.11. Roles of participants in SEQ 2016
Table 2.12. Roles of participants in SEQ 2015
Table 2.13. Main purposes of sequencing activities of participants in SEQ2015
Table 3.1. Fields of work relating to DNA and RNA sequencing of SEQ 2016 participants
Table 3.2. Fields of participants in SEQ 2015
Table 4.1. Laboratory locations of DNA/RNA sequencing of SEQ 2016 participants
Table 5.1. Current disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Table 5.2. Anticipated future disease areas relating to DNA/RNA sequencing of SEQ 2016 participants
Table 5.3. Current disease areas relating to sequencing, of participants in SEQ2015
Table 5.4. Future disease areas relating to sequencing, of participants in SEQ2015
Table 6.1. Current sequencing methods of SEQ 2016 participants
Table 6.2. Future anticipated sequencing methods of SEQ 2016 participants
Table 6.3. Current sequencing techniques, of participants in SEQ2015
Table 6.4. Future sequencing techniques, of participants in SEQ2015
Table 7.1. Current sequencing instruments used by SEQ 2016 participants
Table 7.2. Future anticipated sequencing instruments of SEQ 2016 participants
Table 8.1. Advantages cited by 2016 end-users of the sequencing techniques they use
Table 8.2. Disadvantages cited by 2016 end-users of the sequencing techniques they use
Table 8.3. Top ten advantages of the DNA sequencing techniques, of participants in SEQ 2015
Table 8.4. Top ten disadvantages of the DNA sequencing techniques, of participants in SEQ2015
Table 9.1. Current sequencing applications of SEQ 2016 participants
Table 9.2. Future anticipated sequencing applications of SEQ 2016 participants
Table 9.3. Current applications of sequencing activities, of participants in SEQ2015
Table 9.4. Future applications of sequencing activities, of participants in SEQ 2015
Table 10.1. Current clonal amplification methods of SEQ 2016 participants
Table 10.2. Future clonal amplification methods of SEQ 2016 participants
Table 11.1. Top sequencing software (A – M) used by SEQ 2016 participants
Table 11.2. Top sequencing software (M – Z) used by SEQ 2016 participants
Table 11.3. Software used in DNA sequencing, of participants in SEQ2015
Table 13.1. Current nucleotide types sequenced by SEQ 2016 participants
Table 13.2. Top ten future anticipated nucleotide types to be sequenced by SEQ 2016 participants
Table 13.3. Current nucleic acids types in their sequencing activities, of participants in SEQ2015
Table 13.4. Future nucleic acids types in their sequencing activities, of participants in SEQ2015
Table 14.1. Recent sequencing growth trends of suppliers of SEQ 2016 participants
Table 14.2. Future anticipated sequencing growth trends of SEQ 2016 participants
Table 14.3. Recent trend levels in their sequencing activities, of participants in SEQ2015
Table 14.4. Future anticipated trend levels in their sequencing activities, of participants in SEQ2015
Table 15.1. Current sequencing suppliers of SEQ 2016 participants
Table 15.2. Future sequencing suppliers of SEQ 2016 participants
Table 15.3. Current suppliers in their sequencing activities, of participants in SEQ2015
Table 15.4 Future anticipated suppliers in their sequencing activities, of participants in SEQ 2015
Table 16.1. Samples sequenced sequenced by SEQ 2016 participants
Table 16.2. Study samples in their sequencing activities, of participants in SEQ2015
Table 17.1. Sequencing sample preparation methods used by SEQ 2016 participants
Table 17.2. Main sample preparation methods used in their sequencing activities, of participants in SEQ2015
Table 18.1. The use of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Table 18.3. Preferred suppliers of sample preparation kits in their sequencing activities, of participants in SEQ 2016
Table 19.1. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Table 19.2. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Table 19.3. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2016
Table 19.4. The study of disease biomarkers using DNA or RNA sequencing, by participants in SEQ 2015
Table 20.1. Sample throughput levels in DNA and RNA sequencing, indicated by end-users in SEQ 2016
Table 20.2. Sample throughput levels in DNA and RNA sequencing, indicated by end-users in SEQ 2015
Table 20.3. Per-sample sequencing cost levels in their DNA sequencing activities, of participants in SEQ2015
